Citigroup maintains Becton Dickinson at Buy, raises price target to $241 from $208

Citigroup kept its Buy rating on Becton Dickinson (BDX) and increased its price target to $241 from $208, suggesting a 13.7% upside from its Nov 6 close of $211.88. Recent analyst price targets for BDX range from $165 to $242.

Original reporting
Published Nov 6, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Citigroup maintains Becton Dickinson at Buy, raises price target to $241 from $208 — source image
Decision brief

The 30-second read

$BDXBullishMed
01

Why it matters

The upgrade could trigger buying pressure, but magnitude depends on broader market sentiment.

02

Market read

Analyst target raise provides a modest trading signal for BDX.

03

What to watch

Potential supply‑chain constraints could offset upside.

Relevance 6/10Novelty 5/10Timing: today

Background

Analyst price target adjustments are common catalysts for short‑term moves.

Company-level read

Ticker impact

$BDXBullishMedium confidence
Context

Citigroup raised its price target on Becton Dickinson to $241 from $208.

Expected impact

potential upward pressure as investors price in higher target

Evidence & confidence

Target increase reflects improved outlook, likely to attract buying interest.

Market effects

May lift sentiment in medical devices sector.

US healthcare stocks could see modest gains.

Limited to investors tracking US med‑tech equities.

Counterpoint

Target raise may be premature if upcoming earnings miss expectations.

Key entities

  • Citigroup

    Equity research firm raising BDX target.

  • Becton Dickinson

    Medical device manufacturer.

Related articles

$AAPLMed

New Australian Data Shed Even More Light on Tax Avoidance by Big Tech (and Others), Highlight Need for Better Disclosure in the U.S.

The Australian Taxation Office released country-by-country tax reports, revealing that Apple (25% of profits in Singapore) and Visa (62% of profits in Singapore) booked significant profits in low-tax jurisdictions. Becton Dickinson reported $266.2M pretax income in the Cayman Islands with no local employees. The data highlights discrepancies between U.S. and Australian disclosures, raising concerns about tax transparency.

$BDXMedAI 8/10

Becton, Dickinson and Company Q4 Earnings Call Highlights

Becton, Dickinson (BDX) reported Q4 earnings, with revenue growth in Interventional (7.6%) and BioPharma Systems (7%). The company expects Q1 adjusted EPS of $2.32-$2.37, with full-year margins flat. BDX plans to discuss long-term targets on Dec. 10. Free cash flow rose 42% to $2.9B, with $3.6B returned to shareholders. BDX has a $19B U.S. investment agreement, potentially easing future tariffs.

$BDXHighAI 8/10

Becton Dickinson & Co (BDX) (Q4 2026) Earnings Call Highlights: Strong Q4 Beat, $19

Becton Dickinson (BDX) reported strong Q4 2026 results but issued cautious fiscal 2027 guidance, expecting low single-digit revenue growth due to a 200 basis point Alaris headwind. Adjusted operating margins are expected to remain flat, with inflation and investments offsetting productivity gains. The company's Q1 guidance is conservative, impacted by system cutovers and the Alaris comparison. Tariff relief benefits are not included in the guidance due to uncertainty.